This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Finding smallmoleculedrugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with smallmolecules is even worse.
On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. Ben Miles, Ph.D., Head of Product Management at Strateos was joined by Josh Bond, Director of Product Management at PerkinElmer Informatics to discuss this exciting collaboration. Ben Miles, Ph.D.,
The second is that while it may be hard to achieve molecular recognition, it’s even harder to make a drug, which is to say a molecule that you can eat, that distributes throughout the body, and survives long enough to find its target. Consequently, we were going to stick to chemical space where we know real drugs live.
As a result, Pfizer can maximize uptime for equipment such as centrifuges, agitators, pulverizers, coaters, and air handlers used in clinical drug manufacturing. The overall focus of this collaboration is to support Pfizer in more rapidly and reliably producing new drugs and evaluating their potential health benefit for patients.
On July 20th, Strateos hosted a webinar entitled Drug Discovery and Medicinal Chemistry in the Era of Automation. To advance a lead candidate through to clinical trials in traditional smallmolecule pipelines, it can take on average 6+ years. Daniel Rines, Ph.D., Director of R&D Strategy and Vince Yeh, Ph.D.,
Strateos’ SVP of Strategy & Operations, Daniel Sipes, echoed this sentiment during his presentation on how automated labs are accelerating medicinal chemistry (MedChem) cycles for drug discovery. The model quality data generated is well-suited to support AI and machine learning tools.”
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content